Sexually Transmitted Diseases

Patricia J. Sulak

doi:10.1055/s-2004-815595

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2003; 21(4): 399-414
DOI: 10.1055/s-2004-815595

Sexually Transmitted Diseases

Patricia J. Sulak

Department of Obstetrics and Gynecology, Scott & White Clinic/Memorial Hospital, Temple, Texas

Abstract

ABSTRACT

Sexually transmitted diseases (STDs) constitute a major health burden in the United States, causing pelvic inflammatory disease, ectopic pregnancy, infertility, chronic pelvic pain, genital lesions, genital neoplasms, adverse pregnancy outcomes, immune system dysfunction, liver disease, and even death. STDs disproportionately affect adolescents and young adults. Of the estimated 15 million STDs that occur annually each year in the United States, 4 million are among adolescents and 6 million among young adults. The current epidemic is complicated by the high asymptomatic carrier state associated with most STDs and the inadequate protection of condoms in preventing transmission. Sexually active individuals, particularly adolescents, must be educated on the ramifications of early onset of sexual activity and the health consequences of multiple sexual partners.

KEYWORDS

Sexually transmitted diseases - condoms - consequences - review article

Full Text

References

REFERENCES

1 American Social Health Association/Kaiser Family Foundation. Sexually Transmitted Diseases in America: How Many Cases and at What Cost? Menlo Park, CA: Kaiser Family Foundation; 1998
2 Centers for Disease Control and Prevention. Summary of notifiable diseases-United Sates, 2000. MMWR Morb Mortal Wkly Rep . 2000; 49 1-102
3 Cates Jr W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis . 1999; 26(Suppl) S2-S7
4 Goldenberg R L, Andrews W W, Yuan A C, MacKay H T, St Louis E M. Sexually transmitted diseases and adverse outcomes of pregnancy. Clin Perinatol . 1997; 24 23-41
5 Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. In: Eng T, Butler W, eds. The Hidden Epidemic: Confronting Sexually Transmitted Diseases Washington, DC: National Academy Press; 1997
6 Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines-2002. MMWR . 2002; 51 No.RR-6
7 Cotch M F, Pastorek J G, Nugent R P. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis . 1997; 24 353-360
8 Minkoff H, Grunebaum A N, Schwarz R H. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol . 1984; 150 965-972
9 Klebanoff M, Carey J, Hauth J C. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med . 2001; 345 487-493
10 Laga M, Manoka A, Kivuvu M. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS . 1993; 7 95-102
11 Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV1 transmission. Lancet . 1998; 351 213-214
12 Centers for Disease Control and Prevention. Primary and secondary syphilis: United States, 2000-2001. MMWR Morb Mortal Wkly Rep . 2002; 51 971
13 Centers for Disease Control and Prevention. Congenital Syphilis: United States, 2000. MMWR Morb Mortal Wkly Rep . 2001; 50 573-577
14 Greenblatt R M, Lukehart S A, Plummer F A. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS . 1988; 2 47-50
15 Stamm W E, Handsfield H H, Rompalo A M. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA . 1988; 260 1429-1433
16 Centers for Disease Control and Prevention. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections-2002. MMWR . 2002; 51 No.RR-15
17 Burstein G R, Gaydos C A, Diener-West M. Incident chlamydia trachomatis infections among inner-city adolescent females. JAMA . 1998; 280 521-526
18 Rees E. Treatment of pelvic inflammatory disease. Am J Obstet Gynecol . 1980; 138 1042-1047
19 Stamm W E, Guinan M E, Johnson C. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med . 1984; 310 545-549
20 Westrom L, Joesoef R, Reynolds G. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopy results. Sex Transm Dis . 1992; 19 185-192
21 Fox K K, Whittington W L, Levine W C, Moran J S, Zaidi A A, Nakashima A K. Gonorrhea in the United States, 1981-1996; demographic and geographic trends. Sex Transm Dis . 1998; 25 386-393
22 Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep . 2002; 51 1041-1044
23 Rein D B, Kassler W J, Irwin K L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol . 2000; 95 397-402
24 Wiesenfeld H C, Hillier S L, Krohn M A. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol . 2002; 100 456-463
25 Walker C K, Kahn J G, Washington A E. Pelvic inflammatory disease: meta-analysis of antimicrobial regimen efficacy. J Infect Dis . 1993; 168 969-978
26 Ness R B, Soper D E, Holley R I. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trail. Am J Obstet Gynecol . 2002; 186 929-937
27 Fleming D T, McQuillan G M, Johnson R E. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med . 1997; 337 1105-1111
28 Smith J S, Robinson N J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis . 2002; 186(Suppl 1) S3-28
29 Fisman D N, Lipsitch M, Hook E W. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex Transm Dis . 2002; 29 608-622
30 Szucs T, Berger K, Fisman D, Harbarth S. The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches. BMC Infect Dis . 2001; 1 5
31 Roberts C, Pfister J. Increasing proportion of HSV-1 as a cause of genital herpes infection in college students. Presented at the 2002 National STD Prevention Conference, San Diego; Abstract #LB1
32 Wald A, Zeh J, Selke S. Reactivation of genital HSV-2 infection in asymptomatic seropositive persons. N Engl J Med . 2000; 342 844-850
33 Centers for Disease Control and Prevention. Tracking the Hidden Epidemics: Trends in STDs in the United States, 2000. Atlanta: Centers for Disease Control and Prevention; 2001: 1-31
34 Holmberg S D, Stewart J A, Gerber A R. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA . 1988; 259 1048-1050
35 Pepin J, Plummer F A, Brunham R C. The interaction of HIV infection and other sexually transmitted diseases: an opportunity for intervention. AIDS . 1989; 3 3-9
36 Xu F, Schillinger J A, Sternbert M R. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis . 2002; 185 1019-1024
37 Langenberg A G, Corey L, Ashley R L. A prospective study of new infections with herpes simplex virus type 1 and type 2 Chiron HSV Vaccine Study Group. N Engl J Med . 1999; 341 1432-1438
38 Koutsky L A, Ashley R L, Holmes K K. The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex Transm Dis . 1990; 17 90-94
39 Lafferty W E, Downey L, Celum C. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis . 2000; 181 1454-1457
40 Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med . 1997; 102 3-8
41 Jacobson D L, Womack S D, Peralta L. Concordance of human papillomavirus in the cervix among inner-city adolescents. Pediatr Infect Dis J . 2000; 19 722-728
42 Ho G YF, Bierman R, Beardsley L, Chang C J, Burk R D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med . 1998; 338 423-428
43 Giuliano A, Harris R, Sedjo R. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis . 2002; 186 462-469
44 Kulasingam S L, Hughes J P, Kiviat N B. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA . 2002; 288 1749-1757
45 Adam E, Berkova Z, Daxnerova Z. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am J Obstet Gynecol . 2000; 182 257-264
46 Hildesheim A, Hadjimichael O, Schwartz P E. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol . 1999; 180 571-577
47 American Cancer Society. Cancer Facts and Figures 2002. Available at: www.cancer.org
48 Walboomers J M, Jacobs M V, Manos M M. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol . 1999; 189 12-19
49 DiSaia P J, Creasman W T. Clinical Gynecologic Oncology. 5th ed. St. Louis, MO: Mosby-Year Book; 1997
50 Frisch M, Glimelius B, van den Brule J C A. Sexually transmitted infection as a cause of anal cancer. N Engl J Med . 1997; 337 1350-1358
51 Centers for Disease Control and Prevention. First report of AIDS. MMWR Morb Mortal Wkly Rep . 2001; 50 429
52 UNAIDS. Report on the global HIV/AIDS epidemic, July 2002. Available at: http://www.unaids.org/Barcelona/presskit/ report.htm. Accessed October 21 2002
53 Centers for Disease Control and Prevention. Divisions of HIV/AIDS prevention Basic statistics. Available at: http:// www.cdc.gov/hiv/stats.htm. Accessed November 29 2002
54 Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. MMWR . 2001; 13 2
55 Centers for Disease Control and Prevention. Divisions of HIV/AIDS prevention. Young people at risk: HIV/AIDS among America's youth Available at: http://www.cdc.gov/ hiv/pubs/facts/youth.htm. Accessed January 10 2003
56 Centers for Disease Control and Prevention. HIV testing among pregnant women-United States and Canada, 1998- 2001. MMWR Morb Mortal Wkly Rep . 2002; 51 1013-1016
57 Little S J, Holte S, Routy J P. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med . 2002; 347 385-394
58 Armstrong G L, Bell B P. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics . 2002; 109 839-845
59 Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. MMWR . 1999; 48 No.RR-12
60 McMahon B J, Alward W L, Hall D B. Acute hepatitis B virus infection relation of age to the clinical expression of disease and subsequent development of a carrier state. J Infect Dis . 1985; 151 599-603
61 Lee W. Hepatitis B virus infection. N Engl J Med . 1997; 337 1733-1745
62 Liaw Y F, Tai D I, Chu C M. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology . 1988; 8 493-496
63 Mast E E, Mahoney F J, Alter M J. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine . 1998; 16 S48-S51
64 Alter M J, Kruszon-Moran D, Nainan O V. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med . 1999; 341 556-562
65 Lauer G M, Walker B D. Hepatitis C virus infection. N Engl J Med . 2001; 345 41-52
66 Memon M I, Memon M A. Hepatitis C: an epidemiological review. J Viral Hepat . 2002; 9 84-100
67 Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR . 1998; 47(RR-19) 1-39
68 Terrault N. Sexual activity as a risk factor for hepatitis C. Hepatology . 2002; 36 (suppl 1) S99-S105
69 Delwaide J, Bourgeois N, Colle I. Risk factors for hepatitis C: past, present and future. Acta Gastroenterol Belg . 2002; 65 87-89
70 Koutsky L A, Ault K A, Wheeler C M. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med . 2002; 347 1645-1651
71 Stanberry L R, Spruance S L, Cunningham A L. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med . 2002; 347 1652-1661
72 US Department of Health and Human Services. Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention. July 20, 2001
73 Van Damme L. Advances in topical microbicides (oral). XIII World Conference on HIV/AIDS, Durban, South Africa, 2000
74 Centers for Disease Control and Prevention. Nonoxynol-9 spermicide contraception use-United States, 1999. MMWR Morb Mortal Wkly Rep . 2002; 51 389-392
75 Zeitlin L, Whaley K. Microbicides for preventing transmission of genital herpes. Herpes . 2002; 9 4-9
76 Aral S O. Sexually transmitted diseases: magnitude, determinants and consequences. Int J STD AIDS . 2001; 12 211-215
77 Centers for Disease Control and Prevention. Youth risk behavior surveillance-United States, 2001. MMWR . 2002; 51 No.SS-04
78 Centers for Disease Control and Prevention, Division of Vital Statistics Births: preliminary data for 2001. MMWR . 2002; 50 10